BRÈVE

sur Limes Schlosskliniken AG (isin : DE000A0JDBC7)

Limes Schlosskliniken AG: Strong Growth and Profitability Boost FY25 Performance

Limes Schlosskliniken AG reported impressive preliminary FY25 results, surpassing projections. Revenue surged 40% year-on-year to €53.1 million, driven by robust growth across clinics, particularly at Paracelsus Recovery Clinic in Zurich. The average revenue per patient day increased by 30%, highlighting strong pricing power.

Profitability improved significantly with a 78% increase in EBITDA, reaching €12.8 million. The new clinics, Abtsee and Bergisches Land, contributed to growth, exceeding expectations with Abtsee reaching profitability. EBIT more than doubled to €9.2 million, showcasing scalability.

The management's FY25 outlook was exceeded, with sales initially targeted at €50.8 million and EBITDA at €8.7 million. The cash position nearly doubled to €43 per share, underscoring a cash-generating business model with limited capital intensity.

The company remains optimistic, continuing to guide solid development and strong top-line and earnings expansion. The recommendation remains BUY, with a new target price of €710.

R. P.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Limes Schlosskliniken AG